154 related articles for article (PubMed ID: 32047946)
1. [Chronic lymphocytic leukemia].
Al-Sawaf O; Eichhorst B; Hallek M
Internist (Berl); 2020 Mar; 61(3):277-287. PubMed ID: 32047946
[TBL] [Abstract][Full Text] [Related]
2. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
4. Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
Hanna KS
J Oncol Pharm Pract; 2020 Jan; 26(1):146-155. PubMed ID: 31189420
[TBL] [Abstract][Full Text] [Related]
5. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
6. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
Jain P; Kanagal-Shamanna R; Konoplev S; Zuo Z; Estrov Z
Am J Hematol; 2018 Dec; 93(12):1568-1569. PubMed ID: 30152528
[No Abstract] [Full Text] [Related]
7. Counterpoint: Does Chemoimmunotherapy Still Have a Role in CLL? Chemotherapy Can Be Eliminated in the Management of CLL.
Woyach JA
Oncology (Williston Park); 2018 Jun; 32(6):291, 297, 302. PubMed ID: 29940060
[No Abstract] [Full Text] [Related]
8. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
10. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Molica S
Expert Rev Hematol; 2017 May; 10(5):425-432. PubMed ID: 28349723
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukaemia.
Hallek M; Shanafelt TD; Eichhorst B
Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
15. Relapsed CLL: sequencing, combinations, and novel agents.
Brown JR
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):248-255. PubMed ID: 30504318
[TBL] [Abstract][Full Text] [Related]
16. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
17. Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Pospisilova S; Sutton LA; Malcikova J; Tausch E; Rossi D; Montserrat E; Moreno C; Stamatopoulos K; Gaidano G; Rosenquist R; Ghia P;
Haematologica; 2016 Mar; 101(3):263-5. PubMed ID: 26928246
[No Abstract] [Full Text] [Related]
18. How should we sequence and combine novel therapies in CLL?
Davids MS
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
[TBL] [Abstract][Full Text] [Related]
19. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]